약물계량학을 이용한 초기임상1상 시험 용량 예측 방법에 대한 비교연구

키워드

참고문헌 (98)

1. Adams CP, "Estimating the cost of new drug development:is it really 802 million dollars?", Health Aff, 25(2), pp.420~428 (2006)
2. DiMasi JA, "Trends in risks associated with new drug development: success rates for investigational drugs", Clin Pharmacol Ther, 87(3), pp.272~277 (2010)
3. Investigation of current stage and R&D cost for revitalization of domestic drug discovery & development, "Biotech Policy Research Center", 8~24 (2010)
4. Blume-Kohout ME, "Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development", J Public Econ, 97, pp.327~336 (2013)
5. Morgan SG, "Drug development: Innovation or imitation deficit?", Br Med J, 345, pp.e5880~ (2012)
6. Chung TD, "Collaborative pre-competitive preclinical drug discovery with academics and pharma", biotech partners at Sanford|Burnham:infrastructure, capabilities & operational models, 2014, pp.17(3), 272~289
7. DiMasi JA, "The price of innovation: new estimates of drug development costs", J Health Econ, 22(2), pp.151~185 (2003)
8. "Status of new drug approvals in Korea" (2016)[URL]
9. Zou P, "Applications of human pharmacokinetic prediction in first-in-human dose estimation", AAPS J, 14(2), pp.262~281 (2012)
10. Reagan-Shaw S, "Dose translation from animal to human studies revisited", Fed Am Soc Exp Biol J, 22(3), pp.659~661 (2008)
11. Morgan P, "Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival", Drug Discov. Today, 17(9-10), pp.419~424 (2012)
12. US Food and Drug Administration, "Guidance for industry-Estimating the maximum safe dose in initial clinical trials for therapeutics in adult healthy volunteers", US Food and Drug Administration, ~ (2005)
13. Mahmood I, "Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development", Adv Drug Deliv Rev, 59(11), pp.1177~1192 (2007)
14. Reigner BG, "Estimating the starting dose for entry into humans: principles and practice", Eur J Clin Pharmacol, 57(12), pp.835~845 (2002)
15. Sharma V, "To scale or not to scale: the principles of dose extrapolation", Br J Pharmacol, 157(6), pp.907~921 (2009)
16. Ring BJ, "PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance", J Pharm Sci, 100(10), pp.4090~4110 (2011)
17. Mahmood I, "Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans", J Clin Pharmacol, 40(12 Pt 2), pp.1439~1446 (2000)
18. Boxenbaum H, "Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species", Eur J Drug Metab Pharmacokinet, 9(2), pp.177~183 (1984)
19. Mahmood I, "Prediction of human drug clearance from animal data:application of the rule of exponents and ‘fu Corrected Intercept Method’ (FCIM)", J Pharm Sci, 95(8), pp.1810~1821 (2006)
20. Nagilla R, "A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans", J Pharm Sci, 93(10), pp.2522~2534 (2004)
21. Houston JB, "Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance", Biochem Pharmacol, 47(9), pp.1469~1479 (1994)
22. Obach RS, "The prediction of human clearance from hepatic microsomal metabolism data", Curr Opin Drug Discov Devel, 4(1), pp.36~44 (2001)
23. Shibata Y, "Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method", Drug Metab Dispos, 30(8), pp.892~896 (2002)
24. Goteti K, "Prediction of human drug clearance from two species: a comparison of several allometric methods", J Pharm Sci, 99(3), pp.1601~1613 (2010)
25. Mahmood I, "Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species?", J Pharm Sci, 98(7), pp.2472~2493 (2009)
26. Hakooz N, "Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance", Pharm Res, 23(3), pp.533~539 (2006)
27. Ito K, "Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes", Pharm Res, 21(5), pp.785~792 (2004)
28. Niro R, "Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurements utilizing cryopreserved human hepatocytes", Curr Drug Metab, 4(5), pp.357~369 (2003)
29. Soars MG, "In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance", J Pharmacol Exp Ther, 301(1), pp.382~390 (2002)
30. Brown HS, "Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance", Drug Metab Dispos, 35(2), pp.293~301 (2007)
31. Naritomi Y, "Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans", Drug Metab Dispos, 29(10), pp.1316~1324 (2001)
32. Naritomi Y, "Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro", Drug Metab Dispos, 31(5), pp.580~588 (2003)
33. Zuegge J, "Prediction of hepatic metabolic clearance: comparison and assessment of prediction models", Clin Pharmacokinet, 40(7), pp.553~563 (2001)
34. Fagerholm U, "Prediction of human pharmacokinetics—improving microsome-based predictions of hepatic metabolic clearance", J Pharm Pharmacol, 59(10), pp.1427~1431 (2007)
35. Obach RS, "Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes", Drug Metab Dispos, 27(11), pp.1350~1359 (1999)
36. Stringer R, "Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance", Xenobiotica, 38(10), pp.1313~1329 (2008)
37. Skaggs SM, "A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma", J Pharmacol Toxicol Methods, 53(3), pp.284~290 (2006)
38. Stringer RA, "Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions", Drug Metab Dispos, 37(5), pp.1025~1034 (2009)
39. Galetin A, "Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates", Drug Metab Dispos, 32(12), pp.1411~1420 (2004)
40. Kilford PJ, "Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes", Drug Metab Dispos, 37(1), pp.82~89 (2009)
41. Wajima T, "Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis", J Pharm Sci, 91(12), pp.2489~2499 (2002)
42. Nikolic K, "Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs", J Mol Graph Model, 28(3), pp.245~252 (2009)
43. Schneider G, "Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques", J Med Chem, 42(25), pp.5072~5076 (1999)
44. Jones RD, "PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution", J Pharm Sci, 100(10), pp.4074~4089 (2011)
45. Fagerholm U, "Prediction of human pharmacokinetics—evaluation of methods for prediction of volume of distribution", J Pharm Pharmacol, 59(9), pp.1181~1190 (2007)
46. Ward KW, "A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time", Drug Metab Dispos, 32(6), pp.612~619 (2004)
47. Mahmood I, "Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view", Biopharm Drug Dispos, 18(6), pp.465~473 (1997)
48. Stoner CL, "Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery", Int J Pharm, 269(1), pp.241~249 (2004)
49. Kesisoglou F, "Understanding the effect of API properties on bioavailability through absorption modeling", 10(4), pp.516~525 (2008)
50. Cao X, "Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model", Pharm Res, 23(8), pp.1675~1686 (2006)
51. Andrews CW, "Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship", Pharm Res, 17(6), pp.639~644 (2000)
52. Yoshida F, "QSAR model for drug human oral bioavailability", J Med Chem, 43(13), pp.2575~2585 (2000)
53. Poulin P, "PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach", J Pharm Sci, 100(10), pp.4127~4157 (2011)
54. Obach RS, "The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data", J Pharmacol Exp Ther, 283(1), pp.46~58 (1997)
55. Hosea NA, "Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches", J Clin Pharmacol, 49(5), pp.513~533 (2009)
56. Houston JB, "Progress towards prediction of human pharmacokinetic parameters from in vitro technologies", Drug Metab Rev, 35(4), pp.393~415 (2003)
57. Agoram BM, "Use of pharmacokinetic", pharmacodynamics modelling for starting dose selection in first-in-human trials of high-risk biologics, 2009, pp.67(2), 153~160
58. Heimbach T, "Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data", 11(3), pp.602~614 (2009)
59. Ward KW, "A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time", Drug Metab Dispos, 32(6), pp.612~619 (2004)
60. Obach RS, "Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds", Drug Metab Dispos, 36(7), pp.1385~1405 (2008)
61. Wajima T, "Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles", J Pharm Sci, 93(7), pp.1890~1900 (2004)
62. Fura A, "Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds", Biopharm Drug Dispos, 29(8), pp.455~468 (2008)
63. Gibson CR, "Prediction of phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling", 39(9), pp.637~648 (2009)
64. Lowe PJ, "On setting the first dose in man:quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models", Basic Clin Pharmacol Toxicol, 106(3), pp.195~209 (2010)
65. De Buck SS, "Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs", Drug Metab Dispos, 35(10), pp.1766~1780 (2007)
66. Jones HM, "A novel strategy for physiologically based predictions of human pharmacokinetics", Clin Pharmacokinet, 45(5), pp.511~542 (2006)
67. Dokoumetzidis A, "Modeling and Monte Carlo simulations in oral drug absorption", Basic Clin Pharmacol Toxicol, 96(3), pp.200~205 (2005)
68. Dokoumetzidis A, "Predictive models for oral drug absorption: from in silico methods to integrated dynamical models", Expert Opin Drug Metab Toxicol, 3(4), pp.491~505 (2007)
69. Badhan R, "Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption", J Pharm Sci, 98(6), pp.2180~2197 (2009)
70. Reigner BG, "An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche", Clin Pharmacokinet, 33(2), pp.142~152 (1997)
71. Blackwell B, "For the first time in man", Clin Pharmacol Ther, 13(5), pp.812~826 (1972)
72. US Food and Drug Administration, "Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer", US Food and Drug Administration, ~ (2005)
73. Contrera JF, "Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose", Regul Toxicol Pharmacol, 40(3), pp.185~206 (2004)
74. Rennen MAJ, "Data-based derived values for the inter-species extrapolation, a quantitative analysis of historical toxicity data", Comments Toxicol, 7, pp.423~436 (2001)
75. West GB, "The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization", J Exp Biol, 208, pp.1575~1592 (2005)
76. Bokkers BG, "Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach", Crit Rev Toxicol, 37, pp.355~373 (2007)
77. Suntharalingam G, "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412", N Engl J Med, 355(10), pp.1018~1028 (2006)
78. European Medicines Agency, "Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products", ~ (2007)
79. Lowe PJ, "On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development", Xenobiotica, 37(10-11), pp.1331~1354 (2007)
80. Tang H, "A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry", J Pharm Sci, 95(8), pp.1783~1799 (2006)
81. Iavarone L, "First time in human for GV196771: interspecies scaling applied on dose selection", J Clin Pharmacol, 39(6), pp.560~566 (1999)
82. Mahmood I, "Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance", J Clin Pharmacol, 43(7), pp.692~697 (2003)
83. Sheiner LB, "Pharmacokinetic", pharmacodynamic modeling in drug development, 2000, pp.40, 67~95
84. 윤휘열, "모델 기반학적 신약개발에서 약동", 약력학 모델링 및 시뮬레이션의 역할, 2008, pp.18(2), 84~96[DOI]
85. Lave T, "Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations", Clin Pharmacokinet, 36(3), pp.211~231 (1999)
86. Chiba M, "Prediction of hepatic clearance in human from in vitro data for successful drug development", 11(2), pp.262~276 (2009)
87. Ito K, "Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches", Pharm Res, 22(1), pp.103~112 (2005)
88. Lave T, "The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans", Pharm Res, 14(2), pp.152~155 (1997)
89. Fagerholm U, "The role of permeability in drug ADME", PK, interactions and toxicity—presentation of a permeability-based classification system (PCS) for prediction of ADME, Pharm Res, pp.2008, 25(3)[DOI]
90. Tang H, "Interspecies prediction of human drug clearance based on scaling data from one or two animal species", Drug Metab Dispos, 35(10), pp.1886~1893 (2007)
91. Tang H, "A novel model for prediction of human drug clearance by allometric scaling", Drug Metab Dispos, 33(9), pp.1297~1303 (2005)
92. Lave T, "Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs", J Pharm Sci, 86(5), pp.584~590 (1997)
93. Jones RD, "PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution", J Pharm Sci, 100(10), pp.4074~4089 (2011)
94. Sawada Y, "Prediction of the volumes of distribution of basic drugs in humans based on data from animals", J Pharmacokinet Biopharm, 12(6), pp.587~596 (1984)
95. Yee S, "In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth", Pharm Res, 14(6), pp.763~766 (1997)
96. Kansy M, "Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes", J Med Chem, 41(7), pp.1007~1010 (1998)
97. Sugano K, "Optimized conditions of biomimetic artificial membrane permeation assay", Int J Pharm, 228(1-2), pp.181~188 (2001)
98. Pidgeon C, "IAM chromatography: an in vitro screen for predicting drug membrane permeability", J Med Chem, 38(4), pp.590~594 (1995)

관련 논문AI추천